Liver Forum 17

Print
Liver Forum 17 was held in Paris, France on Wednesday, September 4, 2024

Materials

pdfAgenda

pdfParticipant List

Session I: Meaningful Patient Engagement in Drug Development: Leading Through Example (PEDDLE)

pdfWorking Group Introduction
Michael Betel, Fatty Liver Alliance
Henry Chang, Fatty Liver Foundation*
pdfCase Study #1
Becky Taub, Madrigal Pharmaceuticals
pdfMASH POWER Council Regeneron "Insights to Impact" Case Study
Rosemarie Sellati, Regeneron

Session II: Towards Consensus on NITs

pdfProposal of NITs for a Reasonably Likely Surrogate Endpoint
Richard Haubrich, Forum
Michelle Long, Novo Nordisk
pdfLSM by VCTE as a Reasonably Likely Surrogate Endpoint: Review of the latest clinical evidence
Céline Fournier, Echosens
pdfMRE: Current Data
Michael Middleton, UCSD
Claude Sirlin, UCSD
pdfMapping VCTE and FIB-4 thresholds to matching ELF™ cutoffs
Matthew Gee, Siemens Healthineers

Session III: Forum Placebo Arm Database Data Analysis Plans

pdfForum Placebo Arm Database Updates
Richard Haubrich, Forum
Chris Hoffman, Forum
Margot Yann, Forum
Veronica Miller, Forum

Session IV: MetALD/ALD & Pediatric MASH Working Groups

pdfMetALD/ALD Working Group
Maja Thiele, Odense University
Nikhil Vergis, GSK
MetALD/ALD Working Group Discussion
Jenn Jones, Sober Livers*
Maja Thiele , Odense University
Nikhil Vergis, GSK
pdfPediatric MASH WG
Stavra Xanthakos, Cincinnati Children's Hospital
Miriam Vos, Emory University
Pediatric MASH WG Discussion
All attendees

 

*Remote participation